3 Stocks Underperforming Today In The Diversified Services Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 91 points (0.6%) at 15,720 as of Friday, Feb. 7, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,156 issues advancing vs. 753 declining with 162 unchanged.

The Diversified Services industry currently sits up 0.9% versus the S&P 500, which is up 0.6%. Top gainers within the industry include Aaron's ( AAN), up 12.2%, New Oriental Education & Technology Group I ( EDU), up 5.0%, Priceline.com ( PCLN), up 3.3%, Alliance Data Systems Corporation ( ADS), up 2.6% and Tyco International ( TYC), up 1.3%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Advisory Board Company ( ABCO) is one of the companies pushing the Diversified Services industry lower today. As of noon trading, Advisory Board Company is down $4.97 (-8.1%) to $56.14 on heavy volume. Thus far, 667,422 shares of Advisory Board Company exchanged hands as compared to its average daily volume of 196,500 shares. The stock has ranged in price between $54.79-$60.00 after having opened the day at $58.05 as compared to the previous trading day's close of $61.11.

The Advisory Board Company provides best practices research and analysis, business intelligence and software tools, and management and advisory services to the health care and education industries in the United States and internationally. Advisory Board Company has a market cap of $2.1 billion and is part of the services sector. Shares are down 4.0% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts that rate Advisory Board Company a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Advisory Board Company as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Advisory Board Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Maximus ( MMS) is down $2.70 (-5.4%) to $47.39 on heavy volume. Thus far, 331,222 shares of Maximus exchanged hands as compared to its average daily volume of 403,300 shares. The stock has ranged in price between $47.30-$48.92 after having opened the day at $48.12 as compared to the previous trading day's close of $50.09.

MAXIMUS, Inc. provides business process services to government health and human services agencies in the United States, Australia, Canada, the United Kingdom, and Saudi Arabia. The company operates in two segments, Health Services and Human Services. Maximus has a market cap of $2.8 billion and is part of the services sector. Shares are up 13.9% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts that rate Maximus a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Maximus as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Maximus Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Genpact ( G) is down $2.73 (-15.8%) to $14.50 on heavy volume. Thus far, 6.1 million shares of Genpact exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $13.68-$15.50 after having opened the day at $14.10 as compared to the previous trading day's close of $17.23.

Genpact Limited provides business process management and information technology services worldwide. Genpact has a market cap of $3.9 billion and is part of the services sector. Shares are down 6.2% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate Genpact a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Genpact as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Genpact Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the diversified services industry could consider iShares Dow Jones US Cons Services ( IYC) while those bearish on the diversified services industry could consider ProShares Ultra Short Consumer Sers ( SCC).
null

If you liked this article you might like

These Are the Biggest Winners and Losers in Activist Investing This Year

These Are the Biggest Winners and Losers in Activist Investing This Year

Elliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI

Elliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI

Advisory Breaks Up and Sells Following Elliott Campaign

Advisory Breaks Up and Sells Following Elliott Campaign

Wall Street Weighs In on Athenahealth's Strategic Options

Wall Street Weighs In on Athenahealth's Strategic Options

Singer's Elliott Management Eyes 'Strategic Opportunities' at Athenahealth

Singer's Elliott Management Eyes 'Strategic Opportunities' at Athenahealth